Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonavalent human papillomavirus vaccine - Beijing Health Guard Biotechnology

X
Drug Profile

Nonavalent human papillomavirus vaccine - Beijing Health Guard Biotechnology

Alternative Names: HPV vaccine - Beijing Health Guard Biotechnology; Nonavalent HPV vaccine - Beijing Health Guard Biotechnology; Recombinant nonavalent (types 6/11/16/18/31/33/45/52/58) HPV vaccine - Beijing Health Guard Biotechnology

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Health Guard Biotechnology
  • Class Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Human papillomavirus infections

Most Recent Events

  • 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in China for Human papillomavirus infections in males in 2027 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
  • 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in Indonesia for Human papillomavirus infections (Prevention) in 2025 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
  • 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in China for Human papillomavirus infections (Prevention) in females in 2025 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top